Fundamental Data for CLRT

CLARiENT provides market leading technologies, services and expert support for the characterization, assessment and treatment of cancer, leading to more accurate diagnoses by pathologists, more confident treatment decisions by oncologists, a more efficient way to identify and develop pharmaceuticals and, ultimately, better outcomes for patients.

# Employees: 269

Address: 31 Columbia,Aliso Viejo,CA,USA

Phone: 949-425-5700

Fax: 949-425-5701

Website: www.clarientinc.com

Email: info@clarientinc.com

Sector: Medical

Industry: MED INSTRUMENTS

Executive Officers

Michael J. Pellini M.D. (Presi. C.O.O.)

David J. Daly (Sr. V.P.; Commercial Operations)

James V. Agnello (Sr. V.P.; C.F.O.)

Ronald A. Andrews (C.E.O.)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 3/10/2010

Mean EPS (Next Qtr): $0.01

Mean EPS (Year): ($0.02)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 5

Shares Performance

Period	CLRT	Compare to S&P
YTD	51.53 %	25.41 %
4 Weeks	-26.27 %	-27.06 %
12 Weeks	-38.71 %	-42.22 %

Shares Information

Analyst Coverage: Y

Avg Volume: 892281

Shares Outstanding: 77M

Market Cap: $0.19B

52 Week High: $4.39

52 Week Low: $0.86

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 1/1/1990 CLRT split by factor of 0.200

Earnings Performance

EPS Growth in Last Quarter: 33.33 %

EPS Growth in Last Year: -33.33 %

Sales Growth in Last Quarter: -9.71 %

Sales Growth in Last Quarter: 12.78 %

Financials

Qtr Book Value: ($0.01)

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 2.140